- Diabetes-relevant HLA type: ChiPSC22-derived beta cells originate from a human donor with a diabetes-susceptible HLA type, HLA-A*02:01 (Marron et al. 2002)
- Beta cells from ChiPSC22 can be used alone or in combination with beta cells from ChiPSC12, which have an alternate HLA type
- Cells show protein expression of insulin/C-peptide, MAFA, NKX6.1, PDX1, and UCN3
- Cells demonstrate insulin and C-peptide secretion
- Cells were derived with a protocol that mimics embryonic development
- Cells provide reproducible and biologically relevant data
The tissues used for the reprogramming of somatic cells into hiPSCs are from donors who have signed informed consent which outlines in detail the purpose of the donation and the procedure for processing of the donated tissue. In order to protect the privacy and the confidentiality of the donors, all identifiers associated with the donors have been removed. The donor consent was obtained for commercial use. The donation did not result in any financial gain for the donors.
Cellartis hiPS Beta Cells (from ChiPSC12) (Cat. # Y10100)
Skin fibroblasts from a human 24-year-old adult male (European/North African), healthy volunteer (77 kg/177 cm).
HLA typification data
- HLA-B*08:01, HLA-B*37:01
- HLA-C*06:02, HLA-C*07:01
- HLA-DRB1*03:01, HLA-DRB1*11:04
- HLA-DQB1*02:01, HLA-DQB1*03:01
- HLA-DPB1*01:01, HLA-DPB1*04:01
Cellartis hiPS Beta Cells (from ChiPSC22) (Cat. # Y10106)
Skin fibroblasts from a human 32-year-old adult male (European/North African), healthy volunteer (74 kg/179 cm).
HLA typification data
- HLA-B*07:02, HLA-B*40:01
- HLA-C*03:04, HLA-C*07:02
- HLA-DRB1*13:02, HLA-DRB1*14:01
- HLA-DQB1*05:03, HLA-DQB1*06:04
- HLA-DPB1*03:01, HLA-DPB1*04:01
- Disease modeling for diabetes
- Compound screening for insulin secretion and regulation
- Beta-cell functionality
- GSIS (glucose-stimulated insulin secretion) analysis
- Incretin response studies
- Autoimmune beta-cell destruction
- Pancreatitis and beta-cell function
- 1 vial (4.8 x 106 viable cells) of Cellartis hiPS beta cells from ChiPSC12 or ChiPSC22
- 11 vials (360 µl/vial) of Cellartis Beta Cell Supplement
- 1 tube (4 ml) of Cellartis Beta Cell Coating
- 1 bottle (160 ml) of Cellartis Beta Cell Basal Medium
- 1 bottle (30 ml) of Cellartis Beta Cell Basal Medium 2
Marron, M. et al. Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc Nat Acad Sci U. S. A. 99, 13753–8 (2002).
Additional Product Information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.